B7-33 Research Overview

Simplified Summary

B7-33 was designed as a selective RXFP1 agonist that preserves the anti-fibrotic signalling of the relaxin-2 hormone while reducing its vasodilatory and blood-pressure-lowering properties. Full relaxin has demonstrated anti-fibrotic activity in preclinical models but causes significant haemodynamic effects that limit its therapeutic utility — B7-33's selective design aims to separate anti-fibrotic efficacy from cardiovascular side effects.

Preclinical research using B7-33 has examined fibrotic disease markers in cardiac, pulmonary, and renal tissue models. The compound is administered subcutaneously in animal studies and has been shown to activate RXFP1-mediated signalling cascades associated with extracellular matrix remodelling and collagen turnover.

B7-33 remains in very early preclinical stages with no published human safety or efficacy data. It represents a research tool for understanding RXFP1 biology and the role of the relaxin pathway in fibrotic disease rather than an established protocol compound. Community adoption is extremely limited.

Key Findings Reported in Preclinical Models

• Anti-fibrotic signalling via RXFP1: Preclinical research has demonstrated B7-33's ability to activate RXFP1-mediated pathways associated with collagen degradation and anti-fibrotic gene expression in cardiac and renal tissue models.
• Reduced vasodilatory profile: Comparative studies with full-length relaxin have characterised B7-33's reduced impact on blood pressure and heart rate in animal models, supporting the design hypothesis of separating anti-fibrotic from cardiovascular effects.
• Single-chain stability advantage: Research has examined the pharmacokinetic and stability properties of the single-chain B7-33 design (versus the two-chain relaxin-2 native structure), with manufacturing and handling advantages characterised.
• Cardiac fibrosis models: Preclinical investigation in myocardial fibrosis models has examined ECM marker changes following B7-33 administration, with half-life of approximately 2 hours observed in animal pharmacokinetic studies.
• Very limited human data: No published human safety, pharmacokinetics, or efficacy data exist for B7-33. All mechanistic and biological characterisation derives from in vitro and animal model research.

Introduction

The relaxin family of peptide hormones includes relaxin-2, which has demonstrated significant anti-fibrotic activity in preclinical and early clinical research for conditions including heart failure and pulmonary fibrosis. The full hormone's vasodilatory effects — mediated through RXFP1 and additional pathways — have complicated clinical development for fibrotic indications.

B7-33's design strategy addresses this limitation by retaining the RXFP1-binding B-chain sequence responsible for anti-fibrotic signalling while modifying or removing elements responsible for vasodilatory effects. This structure-activity relationship approach is part of a broader research effort to identify relaxin pathway modulators with improved therapeutic windows.

The compound's research context is that of an exploratory preclinical tool. Researchers working in fibrotic disease biology, RXFP1 signalling, or relaxin pathway modulation may encounter B7-33 in the experimental literature. It is not currently an established protocol compound for community use.

Research Applications

• Fibrotic disease biology: Preclinical models of cardiac, pulmonary, and renal fibrosis using B7-33 as a selective RXFP1 tool to characterise the role of relaxin pathway activation in ECM remodelling.
• Relaxin pathway pharmacology: Structure-activity relationship studies examining which molecular features of relaxin mediate anti-fibrotic versus haemodynamic effects, using B7-33 as a selective probe.
• Heart failure research: Cardiac fibrosis and remodelling models where relaxin signalling has been implicated, using B7-33 to isolate the RXFP1-mediated component of relaxin's cardiac effects.